View in EDS PDF Full Text

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.

Saved in:
Bibliographic Details
Title: A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Authors: Yardley DA; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN. Electronic address: dyardley@tnonc.com., Liggett W; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Mainwaring M; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Castrellon A; Memorial Cancer Institute, Hollywood, FL., Blakely L; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Hemphill B; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Anz B 3rd; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Young RR; The Center for Cancer and Blood Disorders, Fort Worth, TX., Shastry M; Sarah Cannon Research Institute, Nashville, TN., DeBusk LM; Sarah Cannon Research Institute, Nashville, TN., Hainsworth JD; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.
Source: Clinical breast cancer [Clin Breast Cancer] 2020 Apr; Vol. 20 (2), pp. 89-97. Date of Electronic Publication: 2019 Jun 26.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0666
DOI:10.1016/j.clbc.2019.06.005